inclusion criteria: * age ≥ 18 years old * symptomatic infection with covid-19 confirmed by positive rt-pcr sars-cov-2 or, failing that, by thorax ct-scan suggesting viral pneumopathy of peripheral predominance in a clinically significant context. * diagnosis in the previous two calendar days or, for an asymptomatic patient at the time of virological diagnosis, onset of symptoms in the previous two calendar days. * patient having at least one of the following risk factors for developing complications: * age ≥75 years old * age between 60 and 74 years old and presence of at least one comorbidity among the following: obesity (body mass index ≥ 30 kg/m²), arterial hypertension requiring treatment, diabetes mellitus requiring treatment * need for supplemental oxygen to reach a peripheral capillary oxygen saturation of more than 94% (spo2 \> 94%), or a ratio of partial oxygen pressure to the fraction of inspired oxygen less than or equal to 300 mmhg (pao2/fio2 ≤ 300 mmhg). * patient affiliated to a social security scheme. * written and signed consent of the patient or a relative or emergency inclusion procedure. exclusion criteria * last rt-pcr negative for sars-cov-2 * peripheral capillary oxygen saturation less than or equal to 94% (spo2 ≤ 94%) despite oxygen therapy greater than or equal to 3 l/min (\> 3 l/min) * organ failure requiring admission to a critical or intensive care unit. * comorbidity that is life threatening in the short-term (life expectancy \< 3 months) * any reason that makes patient follow-up throughout the study impossible * current treatment with hydroxychloroquine * absolute contraindication to treatment with hydroxychloroquine (known hypersensitivity, retinopathy, concomitant treatment with risk of ventricular disorders, particularly torsades de pointe, known deficit of glucose-6-phosphate dehydrogenase, porphyria) * hypokalaemia \< 3.5 mmol/l * corrected qt prolongation (qtc ≥ 440 ms in men and 460 ms in women). * child-pugh's class c liver cirrhosis * chronic kidney failure with estimated gfr ≤ 30 ml/min, or ≤ 40 ml/min in patients with concomitant treatment with azithromycin * women who are pregnant, breastfeeding, or parturient

inclusion criteria: * age ≥ 18 years old * symptomatic infection with covid-19 confirmed by positive rt-pcr sars-cov-2 or, failing that, by thorax ct-scan suggesting viral pneumopathy of peripheral predominance in a clinically significant context. * diagnosis in the previous two calendar days or, for an asymptomatic patient at the time of virological diagnosis, onset of symptoms in the previous two calendar days. * patient having at least one of the following risk factors for developing complications: * age ≥75 years old * age between 60 and 74 years old and presence of at least one comorbidity among the following: obesity (body mass index ≥ 30 kg/m²), arterial hypertension requiring treatment, diabetes mellitus requiring treatment * need for supplemental oxygen to reach a peripheral capillary oxygen saturation of more than 94% (spo2 \> 94%), or a ratio of partial oxygen pressure to the fraction of inspired oxygen less than or equal to 300 mmhg (pao2/fio2 ≤ 300 mmhg). * patient affiliated to a social security scheme. * written and signed consent of the patient or a relative or emergency inclusion procedure. exclusion criteria * last rt-pcr negative for sars-cov-2 * peripheral capillary oxygen saturation less than or equal to 94% (spo2 ≤ 94%) despite oxygen therapy greater than or equal to 3 l/min (\> 3 l/min) * organ failure requiring admission to a critical or intensive care unit. * comorbidity that is life threatening in the short-term (life expectancy \< 3 months) * any reason that makes patient follow-up throughout the study impossible * current treatment with hydroxychloroquine * absolute contraindication to treatment with hydroxychloroquine (known hypersensitivity, retinopathy, concomitant treatment with risk of ventricular disorders, particularly torsades de pointe, known deficit of glucose-6-phosphate dehydrogenase, porphyria) * hypokalaemia \< 3.5 mmol/l * corrected qt prolongation (qtc ≥ 440 ms in men and 460 ms in women). * child-pugh's class c liver cirrhosis * chronic kidney failure with estimated gfr ≤ 30 ml/min, or ≤ 40 ml/min in patients with concomitant treatment with azithromycin * women who are pregnant, breastfeeding, or parturient

inclusion criteria: - age ≥ 18 years old - symptomatic infection with covid-19 confirmed by positive rt-pcr sars-cov-2 or, failing that, by thorax ct-scan suggesting viral pneumopathy of peripheral predominance in a clinically significant context. - diagnosis in the previous two calendar days or, for an asymptomatic patient at the time of virological diagnosis, onset of symptoms in the previous two calendar days. - patient having at least one of the following risk factors for developing complications: - age ≥75 years old - age between 60 and 74 years old and presence of at least one comorbidity among the following: obesity (body mass index ≥ 30 kg/m²), arterial hypertension requiring treatment, diabetes mellitus requiring treatment - need for supplemental oxygen to reach a peripheral capillary oxygen saturation of more than 94% (spo2 > 94%), or a ratio of partial oxygen pressure to the fraction of inspired oxygen less than or equal to 300 mmhg (pao2/fio2 ≤ 300 mmhg). - patient affiliated to a social security scheme. - written and signed consent of the patient or a relative or emergency inclusion procedure. exclusion criteria - last rt-pcr negative for sars-cov-2 - peripheral capillary oxygen saturation less than or equal to 94% (spo2 ≤ 94%) despite oxygen therapy greater than or equal to 3 l/min (> 3 l/min) - organ failure requiring admission to a critical or intensive care unit. - comorbidity that is life threatening in the short-term (life expectancy < 3 months) - any reason that makes patient follow-up throughout the study impossible - current treatment with hydroxychloroquine - absolute contraindication to treatment with hydroxychloroquine (known hypersensitivity, retinopathy, concomitant treatment with risk of ventricular disorders, particularly torsades de pointe, known deficit of glucose-6-phosphate dehydrogenase, porphyria) - hypokalaemia < 3.5 mmol/l - corrected qt prolongation (qtc ≥ 440 ms in men and 460 ms in women). - child-pugh's class c liver cirrhosis - chronic kidney failure with estimated gfr ≤ 30 ml/min, or ≤ 40 ml/min in patients with concomitant treatment with azithromycin - women who are pregnant, breastfeeding, or parturient

inclusion criteria: - age ≥ 18 years old - symptomatic infection with covid-19 confirmed by positive rt-pcr sars-cov-2 or, failing that, by thorax ct-scan suggesting viral pneumopathy of peripheral predominance in a clinically significant context. - diagnosis in the previous two calendar days or, for an asymptomatic patient at the time of virological diagnosis, onset of symptoms in the previous two calendar days. - patient having at least one of the following risk factors for developing complications: - age ≥75 years old - age between 60 and 74 years old and presence of at least one comorbidity among the following: obesity (body mass index ≥ 30 kg/m²), arterial hypertension requiring treatment, diabetes mellitus requiring treatment - need for supplemental oxygen to reach a peripheral capillary oxygen saturation of more than 94% (spo2 > 94%), or a ratio of partial oxygen pressure to the fraction of inspired oxygen less than or equal to 300 mmhg (pao2/fio2 ≤ 300 mmhg). - patient affiliated to a social security scheme. - written and signed consent of the patient or a relative or emergency inclusion procedure. exclusion criteria - last rt-pcr negative for sars-cov-2 - peripheral capillary oxygen saturation less than or equal to 94% (spo2 ≤ 94%) despite oxygen therapy greater than or equal to 3 l/min (> 3 l/min) - organ failure requiring admission to a critical or intensive care unit. - comorbidity that is life threatening in the short-term (life expectancy < 3 months) - any reason that makes patient follow-up throughout the study impossible - current treatment with hydroxychloroquine - absolute contraindication to treatment with hydroxychloroquine (known hypersensitivity, retinopathy, concomitant treatment with risk of ventricular disorders, particularly torsades de pointe, known deficit of glucose-6-phosphate dehydrogenase, porphyria) - hypokalaemia < 3.5 mmol/l - corrected qt prolongation (qtc ≥ 440 ms in men and 460 ms in women). - child-pugh's class c liver cirrhosis - chronic kidney failure with estimated gfr ≤ 30 ml/min, or ≤ 40 ml/min in patients with concomitant treatment with azithromycin - women who are pregnant, breastfeeding, or parturient